학술논문
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
Document Type
Article
Author
Source
In Annals of Oncology February 2021 32(2):269-278
Subject
Language
ISSN
0923-7534